GSK FDA decision — Mar 19, 2026
✓ APPROVED
GSK plc American Depositary Shares (Each — Linerixibat - (GLISTEN) · Primary biliary cholangitis (PBC).
Run-up into the decision (T-120 → T+5) PDUFA 3/19/26 $61.18 $39.52 10/2/25 Daily close, T-120 (10/2/25) through T+5. Run-up high $61.18 on 2/18/26, low $39.52 on 10/2/25 (T-120 to T-1). FDA decision 3/19/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-03-19
Outcome Approved
Drug / candidate Linerixibat - (GLISTEN)
Company GSK plc American Depositary Shares (Each
120-day run-up (T-120→T-1) +31.7%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio